ArticleThe International journal on drug policy2025
Multilevel determinants of cannabis prices in legal markets: Evidence from products sold in nearly 4000 cannabis dispensaries in the United States.
Article in The International journal on drug policy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Associations between neighborhood disadvantage, cannabis use, and patient-reported outcomes among patients with cancer.Drug and alcohol dependence reports · 2026Article
- Standardizing Recreational Cannabis Excise Tax Rates in the United States: New Retail Price-Based Measurements by Product Category.International journal of environmental research and public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundFollowing cannabis legalization, sales in legal markets have steadily increased. Policies influencing product prices are crucial for cannabis regulation and control. This study aimed to evaluate the determinants of cannabis prices at the product, dispensary, and state levels in legal markets in the United States.
methodsNationwide data on product- and dispensary-level characteristics were collected in 2022 and merged with state-level policy data. The final analysis included 710,588 cannabis flower products from 3,693 dispensaries across 30 states and Washington D.C. with recreational and/or medical cannabis legalization. Multilevel mixed-effects regressions were used to estimate the associations between cannabis prices and product-, dispensary-, and state-level characteristics. Pre-rolls and dried flowers were analyzed separately.
resultsThe average standardized price per gram was $11.72 for pre-rolls and $9.05 for dried flowers, with significant variations across states. A positive association was found between prices and THC level (THC elasticity of price = 0.17, 95 % CI: 0.088, 0.25) and a negative association was found between prices and item weight (weight elasticity of price = -0.18, 95 % CI: -0.22, -0.14). There was limited evidence of associations between prices and dispensary-level characteristics, such as dispensary type (medical vs. recreational), license status, and density of nearby competitors. State tax rates at the retail level were positively associated with prices. These relationships were consistent for both pre-rolls and dried flowers.
conclusionsPolicies targeting potency and item weight may have substantial impacts on cannabis prices in legal markets. Future research is needed to examine how consumers respond to these policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.